Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) featuring a trans-3-hexenoic acid modification at the N-terminus. This structural alteration has been documented in published pharmacological studies to modulate the compound’s receptor interaction and enzymatic stability relative to native GHRH(1-44).
The compound has been extensively referenced in research examining hypothalamic-pituitary axis signaling and somatotroph function. Published investigations have characterized its binding affinity at the GHRH receptor, its effects on pulsatile growth hormone release patterns, and its downstream consequences on IGF-1 axis components in various experimental systems.
Supplied as a sterile lyophilized powder, each 10mg vial is manufactured under controlled conditions and verified through multi-method analytical testing including sequence confirmation and chromatographic purity assessment.
Strictly for research and investigational purposes. Not intended for administration to humans or animals.
